此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

对原发性血小板增多症和羟基脲反应不足或不耐受 (MK-3543-006) 的参与者进行 Bomedemstat (IMG-7289/MK-3543) 与最佳可用疗法 (BAT) 比较的研究

2026年9月30日 更新者:Merck Sharp & Dohme LLC

一项 3 期、随机、开放、主动对照临床研究,旨在评估 Bomedemstat (MK-3543/IMG-7289) 与最佳可用疗法 (BAT) 在患有原发性血小板增多症且血小板不足的患者中的安全性和有效性对羟基脲有反应或不耐受

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).

研究概览

研究类型

介入性

注册 (估计的)

340

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Anhui
      • Bengbu、Anhui、中国、233004
        • The First Afflilated Hospital of Bengbu Medical College ( Site 3509)
      • Hefei、Anhui、中国、230071
        • Anhui Provincial Hospital ( Site 3513)
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100191
        • Peking University Third Hospital-Hematology ( Site 3502)
      • Beijing、Beijing Municipality、中国、100730
        • Peking Union Medical College Hospital ( Site 3531)
    • Fujian
      • Quanzhou、Fujian、中国、362000
        • The Second Affiliated Hospital Of Fujian Medical University ( Site 3525)
      • Xiamen、Fujian、中国、361003
        • The First Affiliated hospital of Xiamen University ( Site 3515)
    • Guangdong
      • Guangzhou、Guangdong、中国、510120
        • Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 3524)
      • Guangzhou、Guangdong、中国、510515
        • Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 3511)
    • Hebei
      • Shijiazhuang、Hebei、中国、050031
        • The First Hospital of Hebei Medical University ( Site 3510)
    • Henan
      • Zhengzhou、Henan、中国、450008
        • Henan Cancer Hospital-hematology department ( Site 3504)
    • Hubei
      • Wuhan、Hubei、中国、430022
        • Wuhan Union Hospital ( Site 3500)
    • Jiangsu
      • Nanjing、Jiangsu、中国、210029
        • Jiangsu Province Hospital ( Site 3507)
      • Nantong、Jiangsu、中国、226001
        • Affiliated Hospital of Nantong University ( Site 3527)
    • Jiangxi
      • Nanchang、Jiangxi、中国、330209
        • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3505)
    • Jilin
      • Changchun、Jilin、中国、130021
        • The First Hospital of Jilin University-Hematology ( Site 3526)
    • Shaanxi
      • Xi'an、Shaanxi、中国、710068
        • Shaanxi provincial people's hospital ( Site 3516)
    • Shandong
      • Jinan、Shandong、中国、250013
        • Jinan Central Hospital ( Site 3523)
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200032
        • Zhongshan Hospital,Fudan University-Hematology ( Site 3530)
      • Shanghai、Shanghai Municipality、中国、200040
        • Huashan Hospital, Fudan University ( Site 3529)
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • West China Hospital, Sichuan University ( Site 3518)
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300020
        • Institute of hematology&blood disease hospital ( Site 3501)
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310003
        • The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3508)
      • Yiwu、Zhejiang、中国、322000
        • Zhejiang University School of Medicine-The Fourth Affiliated Hospital ( Site 3517)
      • Beersheba、以色列、8410101
        • Soroka Medical Center ( Site 2100)
      • Haifa、以色列、3109601
        • Rambam Health Care Campus ( Site 2102)
      • Haifa、以色列、3436212
        • Carmel Hospital ( Site 0906)
      • Jerusalem、以色列、9112001
        • Hadassah Medical Center ( Site 0904)
      • Petah Tikva、以色列、4941492
        • Rabin Medical Center ( Site 0905)
      • Ramat Gan、以色列、5265601
        • Sheba Medical Center ( Site 2101)
      • Tel Aviv、以色列、6423906
        • Sourasky Medical Center ( Site 0902)
      • Tsrifin、以色列、7033001
        • Yitzhak Shamir Medical Center. ( Site 0901)
    • New Brunswick
      • Moncton、New Brunswick、加拿大、E1C 6Z8
        • The Moncton Hospital-Oncology ( Site 1500)
      • Budapest、匈牙利、1088
        • Semmelweis Egyetem-Belgyógyászati és Hematológiai Klinika ( Site 0708)
      • Debrecen、匈牙利、4032
        • Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 0707)
    • Győr-Moson-Sopron
      • Győr、Győr-Moson-Sopron、匈牙利
        • Petz Aladar Egyetemi Oktato Korhaz ( Site 2000)
    • Szabolcs-Szatmár-Bereg
      • Nyíregyháza、Szabolcs-Szatmár-Bereg、匈牙利、4400
        • Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór-Haematológia osztály ( Site 0706)
      • Kaohsiung City、台湾、83301
        • Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 3104)
      • Tainan、台湾、704
        • National Cheng Kung University Hospital-Clinical Trial Center ( Site 3105)
      • Taipei、台湾、10048
        • National Taiwan University Hospital ( Site 3101)
      • Taoyuan、台湾、33305
        • Chang Gung Medical Foundation-Linkou Branch ( Site 3103)
    • Chiayi
      • Chiayi City、Chiayi、台湾、613
        • Chang Gung Memorial Hospital- Chiayi ( Site 3102)
    • Antioquia
      • Medellín、Antioquia、哥伦比亚、050030
        • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1403)
    • Bogota D.C.
      • Bogotá、Bogota D.C.、哥伦比亚、110121
        • Los Cobos Medical Center ( Site 1404)
    • Departamento de Córdoba
      • Montería、Departamento de Córdoba、哥伦比亚、230002
        • IMAT S.A.S ( Site 1401)
      • Ankara、土耳其(türkiye)、06230
        • Hacettepe Universite Hastaneleri-Department of Hematology ( Site 3204)
      • Ankara、土耳其(türkiye)、06620
        • Ankara UTF Cebeci Arastırma ve Uygulama Hastanesi ( Site 3210)
      • Ankara、土耳其(türkiye)、06800
        • Ankara Bilkent Şehir Hastanesi ( Site 3201)
      • Antalya、土耳其(türkiye)、07100
        • Antalya Egitim ve Arastırma Hastanesi ( Site 3207)
      • Edirne、土耳其(türkiye)、22030
        • Trakya University Medical Faculty Hospital-Hematology ( Site 3200)
      • Istanbul、土耳其(türkiye)、34214
        • Medipol Mega Universite Hastanesi-oncology ( Site 3203)
      • Kocaeli、土耳其(türkiye)、41380
        • Kocaeli Üniversitesi-Hematology ( Site 3205)
      • Mersin、土耳其(türkiye)、33440
        • VM Medical Park Mersin Hastanesi ( Site 3208)
      • Samsun、土耳其(türkiye)、55270
        • Ondokuz Mayıs Universitesi-hematology ( Site 3206)
    • İzmir
      • Bornova、İzmir、土耳其(türkiye)、35100
        • Ege Universitesi Hastanesi ( Site 3202)
    • North Rhine-Westphalia
      • Aachen、North Rhine-Westphalia、德国、52074
        • Universitätsklinikum Aachen ( Site 1801)
    • Saxony
      • Dresden、Saxony、德国、01307
        • Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 0402)
    • Saxony-Anhalt
      • Halle、Saxony-Anhalt、德国、06120
        • Universitätsklinikum Halle ( Site 0401)
      • Alessandria、意大利、15121
        • Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 0034)
      • Ancona、意大利、60126
        • Azienda Ospedaliero Universitaria delle Marche ( Site 0302)
      • Reggio Emilia、意大利、42123
        • Arcispedale Santa Maria Nuova ( Site 0301)
      • Torino、意大利、10128
        • Ospedale Mauriziano ( Site 0305)
      • Varese、意大利、21100
        • Ospedale di Circolo e Fondazione Macchi Varese ( Site 2200)
    • Ferrara
      • Cona、Ferrara、意大利、44124
        • Azienda Ospedaliero Universitaria di Ferrara ( Site 0304)
    • Forli-Cesena
      • Meldola、Forli-Cesena、意大利、47014
        • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0308)
    • Lombardy
      • Milan、Lombardy、意大利、20122
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 2201)
    • Tuscany
      • Florence、Tuscany、意大利、50134
        • Azienda Ospedaliera Universitaria Careggi ( Site 0030)
      • Pisa、Tuscany、意大利、56126
        • Azienda Ospedaliero Universitaria Pisana-UO Ematologia UNIV ( Site 0309)
    • Veneto
      • Castelfranco Veneto、Veneto、意大利、31033
        • Istituto Oncologico Veneto IRCCS-Oncoematologia ( Site 0306)
      • Auckland、新西兰、0622
        • North Shore Hospital-Department of Haematology ( Site 0051)
      • Auckland、新西兰、2025
        • Aotearoa Clinical Trials ( Site 0050)
      • Fukuoka、日本、812-8582
        • Kyushu University Hospital ( Site 3605)
      • Fukushima、日本、960-1295
        • Fukushima Medical University Hospital ( Site 3616)
      • Miyazaki、日本、889-1692
        • University of Miyazaki Hospital ( Site 3609)
      • Okayama、日本、700-8558
        • Okayama University Hospital ( Site 3604)
    • Aichi-ken
      • Toyoake、Aichi-ken、日本、470-1192
        • Fujita Health University Hospital ( Site 3613)
    • Chiba
      • Kashiwa、Chiba、日本、277-8577
        • National Cancer Center Hospital East ( Site 3610)
    • Ehime
      • Tōon、Ehime、日本、791-0295
        • Ehime University Hospital ( Site 3612)
    • Hokkaido
      • Sapporo、Hokkaido、日本、060-8648
        • Hokkaido University Hospital ( Site 3601)
    • Hyōgo
      • Kobe、Hyōgo、日本、650-0047
        • Kobe City Medical Center General Hospital ( Site 3603)
    • Ishikawa-ken
      • Kanazawa、Ishikawa-ken、日本、920-8641
        • Kanazawa University Hospital ( Site 3614)
    • Mie-ken
      • Tsu、Mie-ken、日本、514-8507
        • Mie University Hospital ( Site 3615)
    • Miyagi
      • Sendai、Miyagi、日本、983-8520
        • National Hospital Organization Sendai Medical Center ( Site 3617)
    • Osaka
      • Hirakata、Osaka、日本、573-1191
        • Kansai Medical University Hospital ( Site 3607)
      • Sakai、Osaka、日本、590-0197
        • Kindai University Hospital ( Site 3600)
    • Tokyo
      • Bunkyo-ku、Tokyo、日本、113-8431
        • Juntendo University Hospital ( Site 3611)
      • Bunkyo-ku、Tokyo、日本、113-8603
        • Nippon Medical School Hospital ( Site 3608)
    • Yamanashi
      • Chūō、Yamanashi、日本、409-3898
        • University of Yamanashi Hospital ( Site 3606)
      • Antwerp、比利时、2030
        • ZAS Cadix ( Site 1200)
      • Paris、法国、75010
        • Hôpital Saint-Louis-Centre d'Investigations Cliniques ( Site 0405)
    • Brittany Region
      • Rennes、Brittany Region、法国、35000
        • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 0417)
    • Indre-et-Loire
      • Tours、Indre-et-Loire、法国、37000
        • Centre Hospitalier Régional Universitaire de Tours - Hôpital-Hématologie et Thérapie Cellulaire ( Site 0413)
    • Limousin
      • Limoges、Limousin、法国、87042
        • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuyt-Hématologie Clinique et Thérapie Cellu ( Site 1701)
    • Lorraine
      • Vandœuvre-lès-Nancy、Lorraine、法国、54511
        • Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois-HEMATOLOGY ( Site 0407)
    • Nord
      • Roubaix、Nord、法国、59100
        • Centre Hospitalier de Roubaix ( Site 1703)
    • Rhone
      • Pierre-Bénite、Rhone、法国、69310
        • centre hospitalier lyon sud ( Site 0406)
    • Île-de-France Region
      • Paris、Île-de-France Region、法国、75571
        • Hôpital Saint Antoine-Service d'Hématologie et de Thérapie Cellulaire ( Site 1702)
    • Silesian Voivodeship
      • Katowice、Silesian Voivodeship、波兰、40-519
        • Pratia Onkologia Katowice ( Site 0702)
    • Świętokrzyskie Voivodeship
      • Kielce、Świętokrzyskie Voivodeship、波兰、25-734
        • Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S ( Site 2504)
    • New South Wales
      • Camperdown、New South Wales、澳大利亚、2050
        • Royal Prince Alfred Hospital ( Site 1100)
      • Liverpool、New South Wales、澳大利亚、2170
        • Liverpool Hospital-Haematology ( Site 0501)
      • St Leonards、New South Wales、澳大利亚、2065
        • Royal North Shore Hospital ( Site 0003)
      • Waratah、New South Wales、澳大利亚、2298
        • Calvary Mater Newcastle ( Site 0505)
    • South Australia
      • Adelaide、South Australia、澳大利亚、5000
        • Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0001)
    • Victoria
      • Clayton、Victoria、澳大利亚、3168
        • Monash Health-Haematology Research ( Site 0006)
      • Melbourne、Victoria、澳大利亚、3021
        • Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 0502)
    • Western Australia
      • Perth、Western Australia、澳大利亚、6000
        • Royal Perth Hospital-Haematology ( Site 0504)
    • Stockholm County
      • Huddinge、Stockholm County、瑞典、141 86
        • Karolinska Universitetssjukhuset Huddinge ( Site 2900)
    • Örebro County
      • Örebro、Örebro County、瑞典、701 85
        • Universitetssjukhuset Örebro ( Site 0403)
    • Arizona
      • Glendale、Arizona、美国、85304
        • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496)
    • California
      • Glendale、California、美国、91206
        • Los Angeles Cancer Network ( Site 3491)
      • Stanford、California、美国、94305-5826
        • Stanford Cancer Institute ( Site 0107)
      • Torrance、California、美国、90502
        • The Lundquist Institute ( Site 3423)
    • Colorado
      • Aurora、Colorado、美国、80045
        • University of Colorado Anschutz Medical Campus ( Site 3425)
    • Massachusetts
      • Boston、Massachusetts、美国、02111
        • Tufts Medical Center ( Site 3408)
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • University of Michigan ( Site 0008)
      • Detroit、Michigan、美国、48202
        • Henry Ford Hospital ( Site 3413)
    • Nevada
      • Las Vegas、Nevada、美国、89102
        • Optum Care Cancer Center ( Site 3497)
    • New York
      • Buffalo、New York、美国、14263
        • Roswell Park Cancer Institute ( Site 3421)
    • North Carolina
      • Durham、North Carolina、美国、27710
        • Duke University Health System (DUHS) ( Site 0016)
      • Winston-Salem、North Carolina、美国、27157
        • Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400)
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • Medical University of South Carolina-Hollings Cancer Center ( Site 3426)
    • Virginia
      • Charlottesville、Virginia、美国、22908
        • University of Virginia ( Site 3422)
      • Richmond、Virginia、美国、23219
        • VCU Health Adult Outpatient Pavillion ( Site 3416)
      • Manchester、英国、m20 4bx
        • The Christie NHS Foundation Trust ( Site 3307)
    • Cambridgeshire
      • Cambridge、Cambridgeshire、英国、CB2 2QQ
        • Addenbrooke's Hospital ( Site 3303)
    • Gloucestershire
      • Gloucester、Gloucestershire、英国、Gl1 3NN
        • Gloucestershire Royal Hospital ( Site 3302)
    • Great Britain
      • Lincoln、Great Britain、英国、LN2 5QY
        • Lincoln County Hospital ( Site 3310)
    • Lincolnshire
      • Boston、Lincolnshire、英国、PE21 9QS
        • Boston Pilgrim Hospital ( Site 3301)
    • London, City of
      • London、London, City of、英国、NW1 2PG
        • University College London Hospital ( Site 3300)
      • London、London, City of、英国、SE1 9RT
        • Guy's & St Thomas' NHS Foundation Trust ( Site 3305)
      • London、London, City of、英国、SE5 9RS
        • King's College Hospital ( Site 3308)
    • Newport
      • Gwent、Newport、英国、NP20 2UB
        • Royal Gwent Hospital ( Site 3304)
    • Windsor And Maidenhead
      • Windsor、Windsor And Maidenhead、英国、SL4 3HD
        • GenesisCare - Windsor ( Site 3309)
      • Groningen、荷兰、9728 NT
        • Martini Ziekenhuis ( Site 2300)
      • Groningen、荷兰、9700 RB
        • University Medical Center Groningen ( Site 2304)
    • North Holland
      • Hoofddorp、North Holland、荷兰、2134 TM
        • Spaarne Gasthuis - Hoofddorp-Oncology ( Site 2301)
    • South Holland
      • Dordrecht、South Holland、荷兰、3318 AT
        • Albert Schweitzer Ziekenhuis, locatie Dordwijk-Internal Medicine ( Site 2302)
      • Braga、葡萄牙、4710-243
        • Unidade Local de Saude de Braga - Hospital de Braga ( Site 0415)
      • Lisbon、葡萄牙、1449-005
        • Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 2600)
      • Porto、葡萄牙、4200-072
        • Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 0414)
      • Albacete、西班牙、02006
        • Hospital General Universitario de Albacete ( Site 0408)
      • Barcelona、西班牙、08035
        • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0404)
      • Madrid、西班牙、28041
        • Hospital Universitario 12 de Octubre ( Site 2806)
      • Málaga、西班牙、29010
        • Hospital Universitario Virgen de la Victoria ( Site 0418)
      • Salamanca、西班牙、37007
        • Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 0419)
      • Valencia、西班牙、46017
        • Hospital Universitario Doctor Peset ( Site 0411)
    • Barcelona
      • Badalona、Barcelona、西班牙、08916
        • Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 0409)
      • L'Hospitalet Del Llobregat、Barcelona、西班牙、08908
        • Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 2801)
    • Catalonia
      • Barcelona、Catalonia、西班牙、08003
        • Hospital del Mar ( Site 2807)
      • Barcelona、Catalonia、西班牙、08036
        • HOSPITAL CLÍNIC DE BARCELONA ( Site 2800)
    • La Coruna
      • Santiago de Compostela、La Coruna、西班牙、15706
        • CHUS - Hospital Clinico Universitario ( Site 0421)
    • Madrid, Comunidad de
      • Madrid、Madrid, Comunidad de、西班牙、28034
        • Hospital Universitario Ramón y Cajal-Hematology ( Site 2803)
    • Malaga
      • Marbella、Malaga、西班牙、29603
        • Hospital Costa del Sol-Hematology Service ( Site 0412)
    • Buenos Aires
      • Pilar、Buenos Aires、阿根廷、B1629AHJ
        • Hospital Universitario Austral ( Site 0104)
    • Buenos Aires F.D.
      • ABB、Buenos Aires F.D.、阿根廷、C1199ABB
        • Hospital Italiano de Buenos Aires ( Site 0105)
    • Tucumán Province
      • San Miguel de Tucumán、Tucumán Province、阿根廷、T4000IKO
        • C.I.C.E. 9 de Julio ( Site 1001)
      • Seoul、韩国、02841
        • Korea University Anam Hospital ( Site 0604)
      • Seoul、韩国、05505
        • Asan Medical Center ( Site 0603)
      • Seoul、韩国、06591
        • The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 0606)
    • Kyonggi-do
      • Seongnam、Kyonggi-do、韩国、13620
        • Seoul National University Bundang Hospital-Hematology ( Site 0605)
      • Hksar、香港
        • Queen Mary Hospital ( Site 1901)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Has a diagnosis of ET per WHO 2016 diagnostic criteria for myeloproliferative neoplasms (confirmed by a central pathologist)
  • Has a centrally assessed bone marrow fibrosis score of Grade 0 or Grade 1, as per a modified version of the European Consensus Criteria for Grading Myelofibrosis
  • Has a history of inadequate response to or intolerance of hydroxyurea based on modified European LeukemiaNet (ELN) criteria for hydroxyurea resistance or intolerance
  • Has an inadequate or loss of response to their most recent prior ET therapy, requiring a change of cytoreductive therapy
  • Has a platelet count > 450 × 10^9/L (450k /μL) assessed up to 72 hours before first dose of study intervention
  • Has an absolute neutrophil count (ANC) ≥0.75 × 10^9/L assessed up to 72 hours before first dose of study intervention
  • Participants may have received up to 3 prior ET-directed cytoreductive agents including hydroxyurea

Exclusion Criteria:

  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to bomedemstat or lysine demethylase or monoamine oxidase inhibitor (LSDi or MAOi) or the chosen best available therapy (including anagrelide, interferon alfa/pegylated interferon, ruxolitinib, or busulfan) that contraindicates participation
  • History of any illness/impairment of GI function that might interfere with drug absorption (eg, chronic diarrhea or history of gastric bypass surgical procedure), confound the study results or pose an additional risk to the individual by participation in the study
  • Evidence at the time of Screening of increased risk of bleeding
  • History of a malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder
  • Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Bomedemstat

Participants will begin treatment at a dose of 50 mg of bomedemstat daily. Dosage will be adjusted either up or down within specified time parameters for each participant to the dose that provides sufficient exposure to safely inhibit thrombopoiesis to decrease platelet counts to the target range. All participants will be treated daily for up to 52 weeks and are eligible for an extended treatment phase up to an additional 156 weeks.

Oral Capsule

其他名称:
  • IMG-7289
  • MK-3543
  • Bomedemstat tosylate
有源比较器:Best Available Therapy

Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 156 weeks at the investigator's discretion.

Oral Tablet

Oral Capsule

Oral Tablet

Subcutaneous Solution

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Durable Clinicohematologic Response (DCHR) Rate
大体时间:Up to approximately 52 weeks

DCHR rate is the percentage of participants with DCHR, defined as a confirmed reduction of platelet count to ≤400 × 10^9/L and absence of white blood cell (WBC) count elevation to >10 × 10^9/L locally assessed to be due to ET, starting by Week 24 and maintained for at least 24 weeks, and the absence of any thrombotic or major hemorrhagic events or disease progression to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) by Week 52.

Up to approximately 52 weeks

次要结果测量

结果测量
措施说明
大体时间
Clinicohematologic Response (CHR) Rate
大体时间:Up to approximately 52 weeks

CHR rate is the percentage of participants with CHR, defined as a confirmed reduction of platelet count to ≤400 × 10^9/L and absence of WBC count elevation to >10 × 10^9/L locally assessed to be due to ET, maintained for at least 12 weeks, and the absence of any thrombotic or major hemorrhagic events or disease progression to MF, MDS or AML by Week 52.

Up to approximately 52 weeks
Hematologic Response (HR) Rate
大体时间:Up to approximately 52 weeks

HR rate is the percentage of participants with HR, HR is defined as the time from the first confirmed hematologic response to first documented evidence of confirmed platelet increase or confirmed WBC increase after latest confirmed hematologic response date.

Up to approximately 52 weeks
Change From Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Fatigue SF-7a Total Fatigue Score
大体时间:Baseline and pre-specified timepoints through Week 52

The PROMIS Fatigue SF-7a is a 7-item participant-reported assessment that measures both the experience of fatigue and the interference of fatigue on daily activities over the past week. Response options are on a 5-point Likert scale, ranging from 1 = never to 5 = always. The total score is used in the analysis and is obtained by summing keyed scores of all items. Scores can range from 7 to 35, with higher scores indicating greater fatigue.

Baseline and pre-specified timepoints through Week 52
Change From Baseline in Total Symptom Score as Measured on the MFSAF v4.0
大体时间:Baseline and pre-specified timepoints through Week 52

The MFSAF v4.0 is a 7-item participant-reported myelofibrosis symptom assessment which asks respondents to report symptom severity at its worst for each of the 7 items on a 0 (Absent) to 10 (Worst Imaginable) numeric rating scale.

Baseline and pre-specified timepoints through Week 52
Duration of Durable Clinicohematologic Response (DODCHR)
大体时间:Up to approximately 52 weeks

For participants who demonstrate DCHR, DODCHR is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC counts until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to MF, MDS or AML.

Up to approximately 52 weeks
Duration of Clinicohematologic Response (DOCHR)
大体时间:Up to approximately 52 weeks

For participants who demonstrate CHR, DOCHR is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC counts until confirmed increase of platelet and WBC count to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to MF, MDS or AML.

Up to approximately 52 weeks
Duration of Hematologic Response (DOHR)
大体时间:Up to approximately 52 weeks

For participants who demonstrate HR, DOHR is defined as the time from the first confirmed hematologic response to first documented evidence of confirmed platelet increase or confirmed WBC increase after latest confirmed hematologic response date.

Up to approximately 52 weeks
Percentage of Participants with Thrombotic Events
大体时间:Up to approximately 52 weeks

Thrombotic events include but are not limited to new or recurrent acute myocardial infarction, unstable angina, stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, thrombotic digital ischemia, or other thrombotic events.

Up to approximately 52 weeks
Percentage of Participants with Major Hemorrhagic Events
大体时间:Up to approximately 52 weeks

Major hemorrhagic events include but are not limited to fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a decrease in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells.

Up to approximately 52 weeks
Percentage of Participants with Disease Progression to Post-ET MF or MDS/AML
大体时间:Up to approximately 52 weeks

Disease progression rate is the percentage of participants with disease progression, defined as the transformation to post-ET MF, MDS, or AML as assessed by the adjudication committee.

Up to approximately 52 weeks
Number of Participants with An Adverse Event (AE)
大体时间:Up to approximately 52 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Up to approximately 52 weeks
Number of Participants Discontinuing From Study Therapy Due to an AE
大体时间:Up to approximately 52 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Up to approximately 52 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Medical Director、Merck Sharp & Dohme LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年12月31日

初级完成 (估计的)

2027年7月14日

研究完成 (估计的)

2028年8月18日

研究注册日期

首次提交

2023年10月6日

首先提交符合 QC 标准的

2023年10月6日

首次发布 (实际的)

2023年10月12日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 3543-006
  • IMG-7289-CTP-301 (其他标识符:Imagobio)
  • MK-3543-006 (其他标识符:MSD)
  • jRCT2031230658 (注册表标识符:Japan Registry of Clinical Trials (jRCT))
  • U1111-1290-2942 (注册表标识符:UTN)
  • 2023-504865-21-00 (注册表标识符:EU CT)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅